Company Filing History:
2 out of 16 
1 out of 832,761 Years Active: 2007-2013
Title: Camilla Nilsberth: Innovator in Alzheimer's Disease Research
Introduction
Camilla Nilsberth is a prominent inventor based in Norrköping, Sweden. She has made significant contributions to the field of neuroscience, particularly in the research and treatment of Alzheimer's disease. With a total of three patents to her name, Nilsberth's work focuses on innovative approaches to combat this debilitating condition.
Latest Patents
Nilsberth's latest patents include groundbreaking inventions aimed at addressing Alzheimer's disease. One of her notable patents is for antibodies specific for amyloid beta protofibril. This invention relates to a purified antibody or fragment that specifically binds to an Aβ protofibril. The composition that includes such antibodies is intended for use in treating patients suspected of having Alzheimer's disease. Another significant patent is related to the prevention and treatment of Alzheimer's disease through the use of a non-wild type protofibril or compounds with protofibril forming activity. This invention also introduces a peptide, Aβ-Arc, which has high protofibril forming activity and several applications, including antibodies against this peptide for passive immunization against Alzheimer's disease.
Career Highlights
Throughout her career, Nilsberth has worked with various organizations, including Bioarctic Neuroscience AB. Her research has been pivotal in advancing the understanding and treatment of Alzheimer's disease, showcasing her dedication to improving patient outcomes.
Collaborations
Nilsberth has collaborated with notable figures in the field, including Lars Lannfelt and Jan Näslund. These partnerships have further enhanced her research and contributed to the development of innovative solutions for Alzheimer's disease.
Conclusion
Camilla Nilsberth is a trailblazer in Alzheimer's disease research, with her patents reflecting her commitment to finding effective treatments. Her work continues to inspire advancements in neuroscience and offers hope for those affected by this challenging condition.